We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cell Therapy in Chronic Ischemic Heart Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00362388
Recruitment Status : Terminated (low enrollling)
First Posted : August 10, 2006
Last Update Posted : January 27, 2010
Information provided by:

Study Description
Brief Summary:
This study was designed to test the hypothesis that direct injection of bone-marrow cells in the heart may increase the number of blood vessels, ameliorating the heart's performance, and relieving patients from symptoms like angina and/or shortness of breath.

Condition or disease Intervention/treatment Phase
Ischemic Heart Disease Coronary Artery Disease Procedure: Intramyocardial injection of autologous bone marrow cells Phase 3

Detailed Description:

Severe ischemic heart disease (IHD) remains a clinical challenge; many patients with IHD have undergone myocardial revascularization procedures (either percutaneous or surgical) but still remain symptomatic despite maximally tolerated medical therapy. Others are considered non-optimal candidates for a complete myocardial revascularization procedure due to the extension and diffuseness of the disease.

Cell therapy with autologous bone marrow-derived cells (BMC) is a novel therapeutic strategy being tested for many cardiovascular diseases, including heart failure, acute myocardial infarction, chronic ischemic heart disease.

The primary objective of this study is to assess the efficacy of intramyocardial injection of autologous BMC on the myocardial perfusion and left ventricular function as an adjunctive therapy (compared to placebo) in patients undergoing coronary artery bypass surgery (CABG).

The secondary objective of this study is to assess the effect of intramyocardial injection of autologous BMC on functional class (angina/heart failure), functional capacity, global and cardiovascular mortality, and quality of life in patients undergoing coronary artery bypass surgery (CABG).

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery
Study Start Date : January 2006
Estimated Primary Completion Date : November 2008
Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Reduction in the ischemic score (global/regional) at 12 months; increase in left ventricle ejection fraction (LVEF) at 12 months.

Secondary Outcome Measures :
  1. All-cause and cardiovascular mortality during the first year; increase in VO2max, increase in quality of life, reduction in angina/heart failure functional class at 12 months; percentage of patients with a 5% increase in LVEF at 6 and 12 months.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of chronic, severe, diffuse, multivessel atherosclerotic coronary artery disease (CAD) referred for CABG.
  • Echocardiogram-assessed LVEF between 25 and 55% (Simpson's rule).
  • Angina (or equivalent) functional class II to IV (Canadian Cardiovascular Society) despite maximally tolerated medical therapy.
  • Abnormal myocardial perfusion tests:

    i. Cardiac scintigraphy ii. Magnetic resonance imaging iii. Dobutamine-atropine stress-echocardiogram

  • Non-candidates for a percutaneous coronary intervention (PCI) due to ANY of the following:

    i. High risk lesion ii. Extensive lesion iii. Diffuse, small vessel disease

  • Non-candidates for a complete CABG, or candidates for a complete CABG in whom, according to an expert panel, there is a high probability of failure of the grafts due to the extension and severity of the disease, with diffuse, small vessel involvement.
  • To provide a signed, written informed consent, according to the National Guidelines for Clinical Trials.

Exclusion Criteria:

  • Severe valve heart disease requiring surgical repair.
  • Serologic diagnostic of Chagas' disease.
  • Symptoms of heart failure, even from an ischemic etiology, in the absence of objectively documented myocardial ischemia.
  • Malignant ventricular arrhythmias (like VT), unless an ICD have been placed.
  • Any acute coronary syndrome in the past 3 months.
  • End-stage renal disease requiring maintenance dialysis.
  • History of neoplasia.
  • Drug or alcohol abuse.
  • Life expectancy below 2 years.
  • Enrollment in any cell therapy trial in the past 2 years.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00362388

Instituto do Coração de Pernambuco do Real Hospital Português de Beneficência
Recife, PE, Brazil, 52010-040
Irmandade da Santa Casa de Misericórdia
Curitiba, PR, Brazil, 80010-030
Clínica Cardiologyca C. Constantini
Curitiba, PR, Brazil, 80320-320
Instituto Nacional de Cardiologia Laranjeiras (INCL)
Rio de Janeiro, RJ, Brazil, 22240-002
Hospital Pró-Cardíaco
Rio de Janeiro, RJ, Brazil, 22280-000
Heart Institute (InCor), Hospital das Clínicas, University of São Paulo Medical School
São Paulo, SP, Brazil, 05403-900
Sponsors and Collaborators
Ministry of Health, Brazil
Ministry of Science and Technology
Principal Investigator: Sergio A. de Oliveira, MD, PhD Heart Institute (InCor), Hospital das Clinicas, University of São Paulo Medical School
Study Director: Jose Eduardo Krieger, MD, PhD Heart Institute (InCor), Hospital das Clinicas, University of São Paulo Medical School
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00362388     History of Changes
Other Study ID Numbers: EMRTCC-ISQ
First Posted: August 10, 2006    Key Record Dates
Last Update Posted: January 27, 2010
Last Verified: November 2008

Keywords provided by Ministry of Health, Brazil:
Coronary artery disease
Ischemic heart disease
Cardiac surgery

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Pathologic Processes
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases